ACTA NEUROPHARMACOLOGICA››2012,Vol. 2››Issue (5): 40-44.
Previous ArticlesNext Articles
YANG Hui, TAN Xiao-hong
Online:2012-10-26Published:2014-06-27Contact:谭晓虹，女，副教授，硕士；研究方向：神经药理学；Tel：+86-0313-4029306, E-mail: txhzbwzl@126.comAbout author:杨辉，男，副教授，硕士；研究方向：心血管药物合成；E-mail: yangkcer@163.comYANG Hui, TAN Xiao-hong.The Effects of Soluble Epoxide Hydrolase Inhibitors on Cardiovascular and Cerebrovascular System Disease[J]. ACTA NEUROPHARMACOLOGICA, 2012, 2(5): 40-44.
| [1] Jeffrey J Lliff, Nabil J Alkayed. Soluble epoxide hydrolase inhibition: Targeting multiple mechanisms of ischemic brain injury with a single agent [J]. Fut Neurol, 2009, 4(2): 179-199. [2] 王守宝，郭晶，祖勉，等. 人源可溶性环氧化物水解酶（hsEH）抑制剂高通量筛选模型建立及其应用[J].中国药理学通报，2009, 25（suppl）：122. [3] William B Campbell, Debebe Gebremedhin, Phillip F Pratt, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors [J]. Circ Res, 1996, 78(3): 415-423. [4] J Vriens, G Owsianik, B Fisslthaler, et al. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium [J]. Circ Res, 2005, 97(9): 908-915. [5] Hantz C Hercule, Wolf-Hagen Schunck, Volkmar Gross, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice[J]. Arterioscler Thromb Vasc Biol, 2009, 29(1): 54-60. [6] John D Imig, Zhao Xue-ying, Jorge H Capdevila, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension[J]. Hypertension, 2002, 39(2): 690-694. [7] Zhao Xue-ying, Tatsuo Yamamoto, John W Newman, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage [J]. J Am Soc Nephrol, 2004, 15(5): 1244-1253. [8] AI Ding, Fu Yi, Guo De-liang, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo[J]. Proc Natl Acad Sci USA, 2007, 104(21): 9018-9023. [9] Yu Zhi-gang, Xu Feng-yun, Linn M Huse, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids [J]. Circ Res, 2000, 87(11): 992-998. [10] F Catella, J A Lawson, D J Fitzgerald, et al. Endogenous biosynthesis of arachidonic acid epoxides in humans: Increased formation in pregnancy-induced hypertension[J]. Proc Natl Acad Sci USA, 1990, 87(15): 5893-5897. [11] Christopher J Sinal, Masaaki Miyata, Masahiro Tohkin, et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation [J]. J Biol Chem, 2000, 275(51): 40504-40510. [12] Krairerk Athirakul, J Alyce Bradbury, Joan P Graves, et al. Increased blood pressure in mice lacking cytochrome P450 2J5 [J]. FASEB J, 2008, 22(12): 4096-4108. [13] David Loch, Andrew Hoey, Christophe Morisseau, et al. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase[J]. Cell Biochem Biophys, 2007, 47(1): 87-98. [14] Oliver Jung, Ralf P Brandes, In-Hae Kim, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension [J]. Hypertension, 2005, 45(4): 759-765. [15] L I Jing, A C Mairead, N C Praveen, et al. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension [J]. Frontiers in Bioscience, 2008, 13(3): 3480-3487. [16] Marc Reverman, Eduardo Barbosa-Sicard , Eva Dony, et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats [J]. J Hypertens, 2009, 27(2): 322-331. [17] William G Sanders, Christophe Morisseau, Bruce D Hammock, et al. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-in?ammatory effects of a soluble epoxide hydrolase inhibitor [J].Am J Physiol Cell Physiol, 2012, 303(3):C278-C290. [18] Kara R Schmelzer, Lukas Kubala, John W Newman, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation[J]. Proc Natl Acad Sci USA, 2005, 102(28): 9772-9777. [19] Kara R Schmelzer, Bora Inceoglu, Lukas Kubala, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors[J]. Proc Natl Acad Sci, USA 2006, 103(37): 13646-13651. [20] Alexis N. Simpkins, R. Daniel Rudic, Derek A Schreihofer, et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection [J]. Am J Pathol, 2009, 174(6)：2086-2095 [21] Zhang Wen-ri, Takashi Otsuka, Nobuo Sugo，et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia [J]. Stroke, 2008, 39(7): 2073-2078. [22] Anne M Dorrance, Nicole Rupp, David M Pollock, et al. Epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid )(AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats [J]. J Cardiovasc Pharmacol, 2005, 46(6): 842–848. [23] Li Ning, Liu Jun-yan, Valeriy Timofeyev, et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches[J]. J Mol Cell Cardiol, 2009, 47(6)：835-845. [24] Andrew R Kompa, Bing H Wang, Xu Guo-ying, et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction [J]. Int J Cardiol, 2013, 167(1)：210-219. [25] Nassiba Merabet, Jeremy Bellien, Etienne Glevarec, et al. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure [J]. J Mol Cell Cardiol, 2012, 52(3)：660–666. [26] Ai Ding, Pang Wei, Li Nan, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy [J]. Proc Natl Acad Sci USA, 2009, 106(2): 564-569. [27] Xu Dan-yan, Li Ning, He Yuxia, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors [J]. Proc Natl Acad Sci USA, 2006, 103(49): 18733-18738. [28] Myriam Fornage, Cruz A Hinojos, Barbara W Nurowska, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats [J]. Hypertension, 2002, 40(4): 485-490. [29] M Fornage, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats [J]. Hypertension, 2002, 40(4): 485-490.(重复) [30] Myriam Fornage, Eric Boerwinkle, Peter A Doris, et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study [J]. Circulation, 2004, 109(3): 335-339. [31] Michael P Hutchens, Takaaki Nakano, Jennifer Dunlap, et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation[J]. Resuscitation, 2008, 76(1): 89-94. [32] Atsuko Motoki, Matthias J Merkel, William H Packwood, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia reperfusion injury in vivo[J]. Am J Physiol Heart Circ Physiol, 2008, 295(5): H2128- H2134. [33] John M Seubert, Christopher J Sinal, Joan Graves, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function [J]. Circ Res, 2006, 99(4): 442-450. [34] ClinicalTrial Gov. Evaluation of soluble epoxide hydrolase (s-EH) inhibitor in patients with mild to moderate hypertension and impaired glucose tolerance [EB/OL]. http://www.clinicaltrials.gov/ct2/show/NCT00847899?term=NCT00847899&rank=1. [35] Benjamin B Davis, Christophe Morisseau, John W Newman, et al. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition[J]. J Pharmacol Exp Ther, 2006, 316(2): 815-821. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
